Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

ReCode is set to secure up to $15m in funding from the Cystic Fibrosis Foundation to enhance its gene correction research ...

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Intellia Therapeutics (NTLA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 16. Analyst ...

Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...

As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM), the company has presented more ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Super Micro Computer, Inc. SMCI gained 11.1% to $20.64 in pre-market trading after gaining more than 3% on Friday. Fly-E ...